Nonmelanoma Skin Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major nonmelanoma skin cancer markets reached a value of US$ 467.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 621.3 Million by 2034, exhibiting a growth rate (CAGR) of 2.62% during 2024-2034.
The nonmelanoma skin cancer market has been comprehensively analyzed in IMARC's new report titled "Nonmelanoma Skin Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nonmelanoma skin cancer refers to a group of skin cancers that develop from the basal cells or squamous cells of the skin, excluding melanocytes. The most common symptom is the formation of an abnormal growth or lesion on the skin that may vary in size, shape, color, or texture over time. Basal cell carcinoma (BCC), the most prevalent type of nonmelanoma skin cancer, include symptoms like small, shiny, or raised bumps, pink/red patches, and non-healing sores that might bleed or crust. Squamous cell carcinoma (SCC), the second most common disease type, often appears as scaly, red/pink elevated growths that may develop a crust or ulcerate. The diagnostic process usually begins with a thorough examination of the skin, focusing on any suspicious lesions. The healthcare provider will assess the characteristics of the lesion, such as its size, shape, texture, etc. If a suspicious area is identified, skin biopsy can be performed. Various additional procedures, including imaging scans and sentinel lymph node biopsy, are also recommended in some instances to determine the extent of the cancer.
The increasing cases of prolonged exposure to UV radiation that lead to abnormal cell growth and the development of cancerous lesions are primarily driving the nonmelanoma skin cancer market. Besides this, the rising prevalence of several associated risk factors, including weakened immune system, chronic skin inflammation, family history, use of indoor tanning beds or sunlamps, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of Mohs micrographic surgery for treating large, aggressive, or recurrent cancererous cells or those located in cosmetically sensitive areas is also bolstering the market growth. Additionally, the emerging popularity of cryosurgery, which involves freezing nonmelanoma skin cancer cells with liquid nitrogen, is creating a positive outlook for the market. The freezing destroys the abnormal cells, leading to their sloughing off and subsequent healing. Moreover, the inflating demand for immune checkpoint inhibitors, such as pembrolizumab and nivolumab, to enhance the body's immune response against malignant cells is also augmenting the market growth. Apart from this, the increasing application of electronic brachytherapy for treating lesions since it minimizes damage to surrounding tissues, thereby preserving aesthetics and resulting in better cosmetic outcomes compared to other invasive procedures, is expected to drive the nonmelanoma skin cancer market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the nonmelanoma skin cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for nonmelanoma skin cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nonmelanoma skin cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the nonmelanoma skin cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the nonmelanoma skin cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current nonmelanoma skin cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the nonmelanoma skin cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the nonmelanoma skin cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the nonmelanoma skin cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of nonmelanoma skin cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of nonmelanoma skin cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of nonmelanoma skin cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with nonmelanoma skin cancer across the seven major markets?
What is the size of the nonmelanoma skin cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of nonmelanoma skin cancer?
What will be the growth rate of patients across the seven major markets?
Nonmelanoma Skin Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for nonmelanoma skin cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the nonmelanoma skin cancer market?
What are the key regulatory events related to the nonmelanoma skin cancer market?
What is the structure of clinical trial landscape by status related to the nonmelanoma skin cancer market?
What is the structure of clinical trial landscape by phase related to the nonmelanoma skin cancer market?
What is the structure of clinical trial landscape by route of administration related to the nonmelanoma skin cancer market?
The nonmelanoma skin cancer market has been comprehensively analyzed in IMARC's new report titled "Nonmelanoma Skin Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Nonmelanoma skin cancer refers to a group of skin cancers that develop from the basal cells or squamous cells of the skin, excluding melanocytes. The most common symptom is the formation of an abnormal growth or lesion on the skin that may vary in size, shape, color, or texture over time. Basal cell carcinoma (BCC), the most prevalent type of nonmelanoma skin cancer, include symptoms like small, shiny, or raised bumps, pink/red patches, and non-healing sores that might bleed or crust. Squamous cell carcinoma (SCC), the second most common disease type, often appears as scaly, red/pink elevated growths that may develop a crust or ulcerate. The diagnostic process usually begins with a thorough examination of the skin, focusing on any suspicious lesions. The healthcare provider will assess the characteristics of the lesion, such as its size, shape, texture, etc. If a suspicious area is identified, skin biopsy can be performed. Various additional procedures, including imaging scans and sentinel lymph node biopsy, are also recommended in some instances to determine the extent of the cancer.
The increasing cases of prolonged exposure to UV radiation that lead to abnormal cell growth and the development of cancerous lesions are primarily driving the nonmelanoma skin cancer market. Besides this, the rising prevalence of several associated risk factors, including weakened immune system, chronic skin inflammation, family history, use of indoor tanning beds or sunlamps, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of Mohs micrographic surgery for treating large, aggressive, or recurrent cancererous cells or those located in cosmetically sensitive areas is also bolstering the market growth. Additionally, the emerging popularity of cryosurgery, which involves freezing nonmelanoma skin cancer cells with liquid nitrogen, is creating a positive outlook for the market. The freezing destroys the abnormal cells, leading to their sloughing off and subsequent healing. Moreover, the inflating demand for immune checkpoint inhibitors, such as pembrolizumab and nivolumab, to enhance the body's immune response against malignant cells is also augmenting the market growth. Apart from this, the increasing application of electronic brachytherapy for treating lesions since it minimizes damage to surrounding tissues, thereby preserving aesthetics and resulting in better cosmetic outcomes compared to other invasive procedures, is expected to drive the nonmelanoma skin cancer market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the nonmelanoma skin cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for nonmelanoma skin cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the nonmelanoma skin cancer market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the nonmelanoma skin cancer market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the nonmelanoma skin cancer market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current nonmelanoma skin cancer marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the nonmelanoma skin cancer market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the nonmelanoma skin cancer market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the nonmelanoma skin cancer market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of nonmelanoma skin cancer across the seven major markets?
What is the number of prevalent cases (2018-2034) of nonmelanoma skin cancer by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of nonmelanoma skin cancer by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with nonmelanoma skin cancer across the seven major markets?
What is the size of the nonmelanoma skin cancer patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of nonmelanoma skin cancer?
What will be the growth rate of patients across the seven major markets?
Nonmelanoma Skin Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for nonmelanoma skin cancer drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the nonmelanoma skin cancer market?
What are the key regulatory events related to the nonmelanoma skin cancer market?
What is the structure of clinical trial landscape by status related to the nonmelanoma skin cancer market?
What is the structure of clinical trial landscape by phase related to the nonmelanoma skin cancer market?
What is the structure of clinical trial landscape by route of administration related to the nonmelanoma skin cancer market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NONMELANOMA SKIN CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NONMELANOMA SKIN CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NONMELANOMA SKIN CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NONMELANOMA SKIN CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NONMELANOMA SKIN CANCER - UNMET NEEDS
10 NONMELANOMA SKIN CANCER - KEY ENDPOINTS OF TREATMENT
11 NONMELANOMA SKIN CANCER - MARKETED PRODUCTS
11.1 List of Nonmelanoma Skin Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Keytruda (Pembrolizumab) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Bavencio (Avelumab) - Avelumab
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NONMELANOMA SKIN CANCER - PIPELINE DRUGS
12.1 List of Nonmelanoma Skin Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 EscharEx - MediWound
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AIV001 - AiViva BioPharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 STP705 - Sirnaomics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Patidegib - Sol-Gel Technologies
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LTX315 - Lytix Biopharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NONMELANOMA SKIN CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NONMELANOMA SKIN CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NONMELANOMA SKIN CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Nonmelanoma Skin Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Nonmelanoma Skin Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Nonmelanoma Skin Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Nonmelanoma Skin Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Nonmelanoma Skin Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Nonmelanoma Skin Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Nonmelanoma Skin Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Nonmelanoma Skin Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
16 NONMELANOMA SKIN CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NONMELANOMA SKIN CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NONMELANOMA SKIN CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NONMELANOMA SKIN CANCER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NONMELANOMA SKIN CANCER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NONMELANOMA SKIN CANCER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NONMELANOMA SKIN CANCER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NONMELANOMA SKIN CANCER - UNMET NEEDS
10 NONMELANOMA SKIN CANCER - KEY ENDPOINTS OF TREATMENT
11 NONMELANOMA SKIN CANCER - MARKETED PRODUCTS
11.1 List of Nonmelanoma Skin Cancer Marketed Drugs Across the Top 7 Markets
11.1.1 Keytruda (Pembrolizumab) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Libtayo (Cemiplimab) - Regeneron Pharmaceuticals
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Bavencio (Avelumab) - Avelumab
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 NONMELANOMA SKIN CANCER - PIPELINE DRUGS
12.1 List of Nonmelanoma Skin Cancer Pipeline Drugs Across the Top 7 Markets
12.1.1 EscharEx - MediWound
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AIV001 - AiViva BioPharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 STP705 - Sirnaomics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Patidegib - Sol-Gel Technologies
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 LTX315 - Lytix Biopharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. NONMELANOMA SKIN CANCER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. NONMELANOMA SKIN CANCER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NONMELANOMA SKIN CANCER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Nonmelanoma Skin Cancer - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Nonmelanoma Skin Cancer - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Nonmelanoma Skin Cancer - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Nonmelanoma Skin Cancer - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Nonmelanoma Skin Cancer - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Nonmelanoma Skin Cancer - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Nonmelanoma Skin Cancer - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Nonmelanoma Skin Cancer - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Nonmelanoma Skin Cancer - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Nonmelanoma Skin Cancer - Access and Reimbursement Overview
16 NONMELANOMA SKIN CANCER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NONMELANOMA SKIN CANCER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NONMELANOMA SKIN CANCER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
